近日,ISCT(國際細胞治療協(xié)會)和 ICCBBA(國際血庫自動化通用委員會)在 Elsevier旗下期刊《Cytotherapy》上發(fā)布了不同組織來源的間充質(zhì)干細胞縮寫命名的統(tǒng)一標準。
The Cellular Therapy Coding and Labeling Advisory Group of the International Council for Commonality in Blood Banking Automation and the International Society for Cell & Gene Therapy mesenchymal stromal cell (MSC) committee are providing specific recommendations on abbreviating tissue sources of culture-adapted MSCs. These recommendations include using abbreviations d on the ISBT 128 terminology model that specifies standard class names to distinguish cell types and tissue sources for culture-adapted MSCs. Thus, MSCs from bone marrow are MSC(M), MSCs from cord blood are MSC(CB), MSCs from adipose tissue are MSC(AT) and MSCs from Wharton's jelly are MSC(WJ). Additional recommendations include using these abbreviations through the full spectrum of pre-clinical, translational and clinical research for the development of culture-adapted MSC products. This does not apply to basic research focused on investigating the developmental origins, identity or functionalities of endogenous progenitor cells in different tissues. These recommendations will serve to harmonize nomenclature in describing research and development surrounding culture-adapted MSCs, many of which are destined for clinical and/or commercial translation. These recommendations will also serve to align research and development efforts on culture-adapted MSCs with other cell therapy products.
根據(jù)ISBT(國際輸血協(xié)會)的128項術(shù)語模型 (該模型針對標準分類)進行命名以區(qū)分所培養(yǎng)的間充質(zhì)干細胞不同組織來源的細胞類型:骨髓間充質(zhì)干細胞是MSC(M);臍帶血間充質(zhì)干細胞是MSC(CB);脂肪組織間充質(zhì)干細胞是MSC(AT);臍帶間充質(zhì)干細胞是MSC(WJ)。
我們簡單回顧一下, (ISCT)定義的間充質(zhì)干細胞(MSC)的標準,包括:(1)貼壁細胞,(2)多系分化能力,可在體外分化成成骨細胞(Osteoblast)、脂肪細胞(adipocyte)、軟骨細胞(chondrocyte)、肌細胞(myocyte)和其它結(jié)締組織,(3)具有關(guān)鍵表面標志分子,包括:CD29、CD44、CD73、CD105和CD146,并且不具有如下的造血細胞表面標志分子:CD34、CD45、CD14、CD11b,CD79α,CD19和HLA-DR。
ISCT介紹:
ISCT成立于1992年,是一個由臨床醫(yī)生、監(jiān)管機構(gòu)、研究人員、技術(shù)人員和行業(yè)合作伙伴組成的全球性非盈利組織。目前,ISCT由來自60多個國家、5個地理區(qū)域的2400多名細胞治療專家組成。
ISCT是專注于開發(fā)基于細胞療法的臨床前和轉(zhuǎn)化方面的全球領(lǐng)導(dǎo)者,推動了科學(xué)研究向患者創(chuàng)新療法的發(fā)展。ISCT提供了一個獨特的協(xié)作環(huán)境,可解決轉(zhuǎn)化的三個關(guān)鍵領(lǐng)域:學(xué)術(shù),監(jiān)管和商業(yè)化。通過與全球監(jiān)管機構(gòu),學(xué)術(shù)機構(gòu)和行業(yè)合作伙伴的牢固關(guān)系,ISCT引領(lǐng)了護理標準研究的發(fā)展。ISCT成員擁有一個共同的愿景,將細胞和基因療法轉(zhuǎn)化為安全有效的療法,以改善全世界患者的生活。
▎文源:https://www.isctglobal.org;
美賽爾內(nèi)容團隊編輯。